Plain-English translation of NCT07198165 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding an immune-boosting drug called toripalimab to a combination of radiation therapy, chemotherapy, and bevacizumab can improve treatment results for people with advanced rectal cancer. All participants receive short-course radiation followed by chemotherapy with bevacizumab. Half the group will also receive toripalimab to see if this additional medication helps the cancer respond better to treatment and prevents it from spreading.
Advanced rectal cancer is hard to treat, and even with current therapies, some patients experience cancer recurrence or spread. This trial explores whether adding an immune-boosting treatment can help more patients achieve complete remission and reduce the risk of the cancer returning.
You likely qualify if…
You likely don't qualify if…
You will first receive five days of short-course radiation therapy to your pelvis. Then, over the next three months, you will receive four treatment cycles of chemotherapy and bevacizumab given intravenously every three weeks—some participants will also receive toripalimab at the same visits. After completing this treatment, imaging tests will show how well the cancer responded, and your doctor will decide whether you need surgery or can be monitored without surgery. Throughout the study, you'll have regular blood tests and check-ups to monitor your health and how well you're tolerating the treatment.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China